Hydrogen sulfide releasing hydrogel for alleviating cardiac inflammation and protecting against myocardial ischemia-reperfusion injury

J Mater Chem B. 2022 Jul 20;10(28):5344-5351. doi: 10.1039/d2tb00971d.

Abstract

Myocardial infarction is one of the leading causes of death worldwide. Thus, protection against myocardial ischemia-reperfusion injury is particularly important to improve the prognosis of myocardial infarction. Recently, hydrogen sulfide (H2S) has been reported to possess a protective effect against myocardial ischemia-reperfusion injury. However, an effective gas delivery system to release H2S controllably at an appropriate concentration needs to be further investigated. In this study, a new H2S-releasing hydrogel system was constructed and applied in an experimental I/R model of rats. The administration of the hydrogel significantly ameliorated microvascular obstruction, prevented myocardial fibrosis, and attenuated cardiac inflammation. This suggested that the novel H2S-releasing hydrogel represented a promising therapeutic strategy targeting myocardial ischemia-reperfusion injury.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Hydrogels / pharmacology
  • Hydrogels / therapeutic use
  • Hydrogen Sulfide* / pharmacology
  • Hydrogen Sulfide* / therapeutic use
  • Inflammation / drug therapy
  • Myocardial Infarction* / drug therapy
  • Myocardial Reperfusion Injury* / drug therapy
  • Myocardial Reperfusion Injury* / prevention & control
  • Rats

Substances

  • Hydrogels
  • Hydrogen Sulfide